Renier Brentjens is the scientific co-founder of Juno Therapeutics and the Memorial Sloan Kettering Cancer Center Director of Cellular Therapeutics. He is a key international player in the CAR T field and delivered the well-attended MCRC (Manchester Cancer Research Centre) Director’s Lecture on 4th November 2019, detailing his groups past and present immunotherapy research activity. During this presentation Renier acknowledged the early clinical work that had been completed in Manchester in the advanced therapy setting and positively recognised the potential of the ATTC model in driving the UK forward in delivering these treatments both through standard care and clinical trials.
Fiona Thistlethwaite, Director of iMATCH, hosted Renier and presented him with a small gift as an appreciation of his time and input.
As part of his time in Manchester, Renier also met with scientists based at the MCRC and Alderley Park and visited the adult and paediatric transplant units, the paediatric gene and cell therapy unit and the stem cell lab at Manchester University Foundation Trust.
